Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
Sponsor: ModernaTX, Inc.
This PHASE1 trial investigates COVID-19 and COVID-19 Immunisation and is currently completed. ModernaTX, Inc. leads this study, which shows 16 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Apr 2024 [monthly]
Completed PHASE1
-
Jul 2023 — Oct 2023 [monthly]
Completed PHASE1
▶ Show 11 earlier versions
-
Jan 2023 — Jul 2023 [monthly]
Completed PHASE1
-
Sep 2022 — Jan 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .